[HTML][HTML] Multivalent protein-drug conjugates–An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells

N Porębska, K Ciura, A Chorążewska… - Biotechnology …, 2023 - Elsevier
With almost 20 million new cases per year, cancer constitutes one of the most important
challenges for public health systems. Unlike traditional chemotherapy, targeted anti-cancer …

Targeting cellular trafficking of fibroblast growth factor receptors as a strategy for selective cancer treatment

N Porębska, M Latko, M Kucińska… - Journal of clinical …, 2018 - mdpi.com
Fibroblast growth factor receptors (FGFRs) in response to fibroblast growth factors (FGFs)
transmit signals across the cell membrane, regulating important cellular processes, like …

Peritoneal spread of ovarian cancer harbors therapeutic vulnerabilities regulated by FOXM1 and EGFR/ERBB2 signaling

D Parashar, B Nair, A Geethadevi, J George, A Nair… - Cancer research, 2020 - AACR
Peritoneal spread is the primary mechanism of metastasis of ovarian cancer, and survival of
ovarian cancer cells in the peritoneal cavity as nonadherent spheroids and their adherence …

High-throughput epitope binning assays on label-free array-based biosensors can yield exquisite epitope discrimination that facilitates the selection of monoclonal …

YN Abdiche, A Miles, J Eckman, D Foletti… - PloS one, 2014 - journals.plos.org
Here, we demonstrate how array-based label-free biosensors can be applied to the
multiplexed interaction analysis of large panels of analyte/ligand pairs, such as the epitope …

Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer

B Fauvel, A Yasri - MAbs, 2014 - Taylor & Francis
Approximately 30 therapeutic monoclonal antibodies have already been approved for
cancers and inflammatory diseases, and monoclonal antibodies continue to be one of the …

Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells

FR Jamnani, F Rahbarizadeh, MA Shokrgozar… - Experimental cell …, 2012 - Elsevier
Modern anti-HER2 antibody therapy tends to exploit a panel of different antibodies against
different epitopes on the antigen. For this aim, nanobodies are very striking targeting agents …

An insight into morphometric descriptors of cell shape that pertain to regenerative medicine

J Lobo, EYS See, M Biggs… - Journal of tissue …, 2016 - Wiley Online Library
Cellular morphology has recently been indicated as a powerful indicator of cellular function.
The analysis of cell shape has evolved from rudimentary forms of microscopic visual …

ERBB oncogene proteins as targets for monoclonal antibodies

OL Polanovski, EN Lebedenko, SM Deyev - Biochemistry (Moscow), 2012 - Springer
General properties of the family of tyrosine kinase ERBB receptors are considered in
connection with their role in the generation of cascades of signal transduction in normal and …

[PDF][PDF] ERBB онкогены-мишени моноклональных антител

ОЛ Поляновский, ЕН Лебеденко, СМ Деев - Биохимия, 2012 - ibch.ru
Рассмотрены свойства семейства тирозинкиназных ERBB рецепторов и определена
их роль в генерации каскадных процессов передачи сигнала в живой клетке в норме и …

[HTML][HTML] Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma

L Fattore, D Malpicci, E Marra, F Belleudi, A Noto… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Patients with metastatic melanoma bearing V600 mutations in BRAF oncogene clinically
benefit from the treatment with BRAF inhibitors alone or in combination with MEK inhibitors …